CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Stopped PI Left institution on 8/6/2018 and study has been final reported with IRB. Never opened to accrual
Conditions
- Pancreatic Ductal Adenocarcinoma
Interventions
- DRUG: CPI-613
- DRUG: mFOLFIRNOX
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators